Evidence map›Paper›PMID 42221109›Full record

Trial reportFrontiers in medicine2026

A machine learning-based classification model for interstitial lung disease in rheumatoid arthritis.

Mingyao Li, Qiaoli Wang, Junfeng He, Xia Wang, Yangyang Xu, Liwei Yang, Lin Feng

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingyao Li *Department of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.
Qiaoli Wang *Health Management Center, Deyang People's Hospital, Deyang, Sichuan, China.
Junfeng HeDepartment of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.
Xia WangDepartment of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.
Yangyang XuDepartment of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.
Liwei YangDepartment of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.
Lin FengDepartment of Rheumatology and Immunology, Deyang People's Hospital, Deyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to develop and validate a preliminary classification and diagnostic model for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) using routine, readily available clinical and laboratory parameters. Multiple machine learning algorithms were employed to construct a practical risk assessment tool suitable for use in primary hospital settings. Methods: Clinical data were retrospectively collected. Patients were divided into RA and RA-ILD groups. After preprocessing, the cohort was randomly divided into training and validation sets. Variables demonstrating a trend toward significance on univariate analysis were subjected to LASSO regression, and feature variables were ultimately identified. Five machine learning models were constructed: CatBoost, logistic regression, support vector machine, decision tree, and random forest. Model performance was assessed on the validation set using accuracy, precision, recall, F1 score, and the area under the receiver operating characteristic (ROC) curve (AUC). The SHapley Additive exPlanations (SHAP) framework was used to identify key features and quantify their contributions to the optimal predictive model. Results: A total of 410 patients with RA were enrolled, among whom 100 (24.39%) were diagnosed with RA-ILD. 23 variables with a trend toward significance on univariate analysis were subjected to LASSO regression. Finally, seven features were selected for model construction: age, smoking history, LYMPH, LDH, RF, CA125, and CA199. Based on these features, five machine learning models were established for RA-ILD classification. In the validation set, the CatBoost model achieved the highest AUC of 0.784 (95% CI: 0.656-0.885) and the lowest Brier score of 0.158, demonstrating robust overall performance. The decision tree (DT) model exhibited comparable discriminatory ability, with an AUC of 0.783 (95% CI: 0.661-0.818), and attained the highest recall (0.653) and F1-score (0.603) across all models, reflecting strong classification efficacy. Conclusion: Among the five evaluated models, CatBoost and DT models showed comparable and favorable overall performance for RA-ILD classification. SHAP analysis based on the CatBoost model identified CA199, CA125, and age as the most important contributors to model prediction. Both models hold promise for RA-ILD risk stratification in clinical practice, although further external validation is warranted.

Indexed as

CatBoostinterstitial lung diseasemachine learningrheumatoid arthritisrisk classification model

Identifiers

PMID42221109
PMCPMC13215908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.